SUBSCRIBE
SUBSCRIBE
News   Policy

Neurocrine Biosciences, Inc. Shares Fall On Drug Worries

April 26, 2006 | 
1 min read
Shares of Neurocrine Biosciences Inc. fell Tuesday despite reporting earnings that beat Wall Street's estimates, as analysts focused on Food and Drug Administration's looming decision on the company's insomnia treatment instead.
Regulatory
Pfizer
MORE ON THIS TOPIC
FDA signage at its headquarters in Maryland
FDA
FDA’s Commissioner’s Priority Voucher Program ‘Shrouded in Secrecy,’ Democratic Rep Says
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
External view of the U.S. Capitol building at sunset
Rare diseases
Rare Pediatric Disease Vouchers Reauthorized, PBM Reform Funded in Narrowly Passed Spending Bill
February 3, 2026
 · 
3 min read
 · 
Heather McKenzie
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Manufacturing
FDA Launches PreCheck Program, Intended To Bring Manufacturers Home
February 2, 2026
 · 
2 min read
 · 
Tristan Manalac